<p>根据 Kennedy Capital Management LLC 最近向证券交易委员会提交的 13F 文件，该公司在第二季度将其在 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免费报告）股票中的持股增加了 380.2%。该公司在季度内额外购买了 22,133 股后，持有 27,955 股。根据其最近的 SEC 文件，Kennedy Capital Management LLC 持有 Axsome Therapeutics 的股份占比为 0.06%，价值 2,918,000 美元。</p>
<p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
<ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
<p>其他一些对冲基金也增加或减少了在 AXSM 的持股。Caitong International Asset Management Co. Ltd 在第一季度购买了价值约 25,000 美元的 Axsome Therapeutics 新股份。Quantbot Technologies LP 在第一季度收购了价值约 31,000 美元的 Axsome Therapeutics 新股份。AlphaQuest LLC 在第一季度收购了价值 38,000 美元的 Axsome Therapeutics 新股份。BI Asset Management Fondsmaeglerselskab A S 在第一季度购买了价值约 47,000 美元的 Axsome Therapeutics 新股份。最后，Ameritas Advisory Services LLC 在第二季度购买了价值约 77,000 美元的 Axsome Therapeutics 新股份。目前，81.49% 的股票由机构投资者持有。</p>
<h2>内部买卖</h2>
<p>在相关消息中，首席运营官 Mark L. Jacobson 于 9 月 22 日星期一出售了 10,000 股该股票。股票以 115.96 美元的平均价格出售，总价值为 1,159,600.00 美元。该交易在 SEC 的法律文件中披露，相关信息可通过此超链接获取。此外，首席执行官 Herriot Tabuteau 于 12 月 4 日星期四出售了 10,558 股公司的股票。股票以 148.18 美元的平均价格出售，总价值为 1,564,484.44 美元。交易后，首席执行官直接持有 7,229 股公司的股票，价值 1,071,193.22 美元。该交易使其持股减少了 59.36%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士出售了价值 52,645,040 美元的 407,959 股公司股票。内部人士持有公司 22.30% 的股票。</p>
<h2>Axsome Therapeutics 价格表现</h2>
<ul>
<li>struggling Axsome 股票可能因药物试验成功而反弹</li>
</ul>
<p>AXSM 的股票在周五开盘价为 149.22 美元。该公司的 50 日移动平均价格为 134.97 美元，200 日移动平均价格为 118.87 美元。该股票的市值为 75.2 亿美元，市盈率为-31.95，贝塔值为 0.48。该公司的债务与股本比率为 1.66，流动比率为 1.57，速动比率为 1.50。Axsome Therapeutics, Inc.的 1 年最低价为 75.56 美元，1 年最高价为 152.94 美元。</p>
<p>Axsome Therapeutics（NASDAQ:AXSM - 获取免费报告）最近在 11 月 3 日星期一发布了季度收益数据。该公司报告季度每股收益（EPS）为（0.94 美元），低于市场共识预期的（0.82 美元）0.12 美元。Axsome Therapeutics 的股本回报率为-277.31%，净利润率为-40.90%。该业务在本季度的收入为 1.7099 亿美元，而分析师预期为 1.6296 亿美元。Axsome Therapeutics 的季度收入同比增长 63.2%。作为一个整体，卖方分析师预计 Axsome Therapeutics, Inc.在当前年度将发布-2.79 的每股收益。</p>
<h2>分析师评级变动</h2>
<ul>
<li>为什么现在是购买 Axsome Therapeutics 的绝佳时机</li>
</ul>
<p>几位股票分析师最近对该公司进行了评估。Needham &amp; Company LLC 重申了对 Axsome Therapeutics 股票的 “买入” 评级，并在 11 月 4 日的研究报告中给出了 154.00 美元的目标价。加拿大皇家银行将 Axsome Therapeutics 的目标价从 189.00 美元上调至 198.00 美元，并在 11 月 4 日的研究报告中给予该公司 “跑赢大盘” 的评级。瑞穗证券在 11 月 6 日的报告中将 Axsome Therapeutics 的目标价从 200.00 美元上调至 202.00 美元，并给予该股票 “跑赢大盘” 的评级。摩根士丹利在 11 月 4 日的报告中将 Axsome Therapeutics 的目标价从 194.00 美元上调至 196.00 美元，并给予该公司 “增持” 的评级。最后，B. Riley 在 10 月 1 日的研究报告中开始覆盖 Axsome Therapeutics 的股票。他们设定了 “买入” 评级和 179.00 美元的目标价。一位股票研究分析师对该股票给予了强烈买入评级，十六位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价为 179.88 美元。</p>
<p><strong>查看我们关于 Axsome Therapeutics 的最新报告</strong></p>
<h2>关于 Axsome Therapeutics</h2>
<p>（免费报告）</p>
<p>Axsome Therapeutics, Inc.是一家生物制药公司，专注于在美国开发针对中枢神经系统（CNS）疾病的新疗法。该公司的商业产品组合包括 Auvelity（右美沙芬 - 布普洛尼），这是一种具有多重作用的 N-甲基-D-天冬氨酸受体拮抗剂，适用于治疗重度抑郁症；以及 Sunosi（索利美特），这是一种用于治疗嗜睡症或阻塞性睡眠呼吸暂停患者的白天过度嗜睡的药物。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过 Axsome Therapeutics</li>
<li>投资者如何识别并成功交易缺口下跌股票</li>
<li>Ulta 的股票可能会迎来反弹——20% 的上涨空间？</li>
<li>最佳航空航天股票投资</li>
<li>比尔和梅琳达·盖茨基金会出售 MSFT 股票——投资者应该担心吗？</li>
<li>股息捕捉策略：您需要知道的事项</li>
<li>MarketBeat 周回顾 – 12/1 - 12/5</li>
</ul>
<p><strong>想看看其他对冲基金持有 AXSM 的情况吗？</strong> 访问 HoldingsChannel.com 以获取 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
<p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Axsome Therapeutics 并不在名单上。</p>
<p>虽然 Axsome Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AXSM

<p>肯尼迪资本管理公司在第二季度将其在 Axsome Therapeutics, Inc.的持股增加了 380.2%，目前持有 27,955 股，价值 2,918,000 美元。分析师们给予了积极的评级，目标价格范围在 154 美元到 202 美元之间，显示出潜在的增长。内部人士在过去 90 天内出售了价值 52,645,040 美元的股票。Axsome 的股票开盘价为 149.22 美元，市值为 75.2 亿美元</p>

<p>Kennedy Capital Management LLC boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 380.2% in the second quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 27,955 shares of the company's stock after acquiring an additional 22,133 shares during the quarter. Kennedy Capital Management LLC owned 0.06% of Axsome Therapeutics worth $2,918,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据 Kennedy Capital Management LLC 最近向证券交易委员会提交的 13F 文件，该公司在第二季度将其在 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免费报告）股票中的持股增加了 380.2%。该公司在季度内额外购买了 22,133 股后，持有 27,955 股。根据其最近的 SEC 文件，Kennedy Capital Management LLC 持有 Axsome Therapeutics 的股份占比为 0.06%，价值 2,918,000 美元。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗股票的收益增长超过三位数</li>
</ul>
</div><p>A number of other hedge funds have also added to or reduced their stakes in AXSM. Caitong International Asset Management Co. Ltd bought a new stake in Axsome Therapeutics during the first quarter valued at about $25,000. Quantbot Technologies LP acquired a new stake in shares of Axsome Therapeutics during the first quarter worth about $31,000. AlphaQuest LLC acquired a new stake in shares of Axsome Therapeutics in the first quarter worth $38,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Axsome Therapeutics during the 1st quarter valued at about $47,000. Finally, Ameritas Advisory Services LLC purchased a new position in Axsome Therapeutics during the second quarter valued at approximately $77,000. 81.49% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金也增加或减少了在 AXSM 的持股。Caitong International Asset Management Co. Ltd 在第一季度购买了价值约 25,000 美元的 Axsome Therapeutics 新股份。Quantbot Technologies LP 在第一季度收购了价值约 31,000 美元的 Axsome Therapeutics 新股份。AlphaQuest LLC 在第一季度收购了价值 38,000 美元的 Axsome Therapeutics 新股份。BI Asset Management Fondsmaeglerselskab A S 在第一季度购买了价值约 47,000 美元的 Axsome Therapeutics 新股份。最后，Ameritas Advisory Services LLC 在第二季度购买了价值约 77,000 美元的 Axsome Therapeutics 新股份。目前，81.49% 的股票由机构投资者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, COO Mark L. Jacobson sold 10,000 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $115.96, for a total value of $1,159,600.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Herriot Tabuteau sold 10,558 shares of the firm's stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $148.18, for a total value of $1,564,484.44. Following the transaction, the chief executive officer directly owned 7,229 shares of the company's stock, valued at $1,071,193.22. The trade was a 59.36% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 407,959 shares of company stock worth $52,645,040. Insiders own 22.30% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席运营官 Mark L. Jacobson 于 9 月 22 日星期一出售了 10,000 股该股票。股票以 115.96 美元的平均价格出售，总价值为 1,159,600.00 美元。该交易在 SEC 的法律文件中披露，相关信息可通过此超链接获取。此外，首席执行官 Herriot Tabuteau 于 12 月 4 日星期四出售了 10,558 股公司的股票。股票以 148.18 美元的平均价格出售，总价值为 1,564,484.44 美元。交易后，首席执行官直接持有 7,229 股公司的股票，价值 1,071,193.22 美元。该交易使其持股减少了 59.36%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士出售了价值 52,645,040 美元的 407,959 股公司股票。内部人士持有公司 22.30% 的股票。</p>
</div><h2>Axsome Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 价格表现</h2>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>struggling Axsome 股票可能因药物试验成功而反弹</li>
</ul>
</div><p>Shares of AXSM opened at $149.22 on Friday. The firm has a fifty day moving average price of $134.97 and a 200 day moving average price of $118.87. The stock has a market cap of $7.52 billion, a PE ratio of -31.95 and a beta of 0.48. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. Axsome Therapeutics, Inc. has a 1-year low of $75.56 and a 1-year high of $152.94.</p>
<div class="lb-trans"><p>AXSM 的股票在周五开盘价为 149.22 美元。该公司的 50 日移动平均价格为 134.97 美元，200 日移动平均价格为 118.87 美元。该股票的市值为 75.2 亿美元，市盈率为-31.95，贝塔值为 0.48。该公司的债务与股本比率为 1.66，流动比率为 1.57，速动比率为 1.50。Axsome Therapeutics, Inc.的 1 年最低价为 75.56 美元，1 年最高价为 152.94 美元。</p>
</div><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The business had revenue of $170.99 million for the quarter, compared to analysts' expectations of $162.96 million. Axsome Therapeutics's quarterly revenue was up 63.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.</p>
<div class="lb-trans"><p>Axsome Therapeutics（NASDAQ:AXSM - 获取免费报告）最近在 11 月 3 日星期一发布了季度收益数据。该公司报告季度每股收益（EPS）为（0.94 美元），低于市场共识预期的（0.82 美元）0.12 美元。Axsome Therapeutics 的股本回报率为-277.31%，净利润率为-40.90%。该业务在本季度的收入为 1.7099 亿美元，而分析师预期为 1.6296 亿美元。Axsome Therapeutics 的季度收入同比增长 63.2%。作为一个整体，卖方分析师预计 Axsome Therapeutics, Inc.在当前年度将发布-2.79 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Why this is an Awesome Time to Buy Axsome Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么现在是购买 Axsome Therapeutics 的绝佳时机</li>
</ul>
</div><p>Several equities analysts recently weighed in on the company. Needham &amp; Company LLC restated a &#34;buy&#34; rating and issued a $154.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, November 4th. Royal Bank Of Canada upped their price objective on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, November 4th. Mizuho lifted their price target on Axsome Therapeutics from $200.00 to $202.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, November 6th. Morgan Stanley upped their price objective on Axsome Therapeutics from $194.00 to $196.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, November 4th. Finally, B. Riley started coverage on shares of Axsome Therapeutics in a research report on Wednesday, October 1st. They set a &#34;buy&#34; rating and a $179.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $179.88.</p>
<div class="lb-trans"><p>几位股票分析师最近对该公司进行了评估。Needham &amp; Company LLC 重申了对 Axsome Therapeutics 股票的 “买入” 评级，并在 11 月 4 日的研究报告中给出了 154.00 美元的目标价。加拿大皇家银行将 Axsome Therapeutics 的目标价从 189.00 美元上调至 198.00 美元，并在 11 月 4 日的研究报告中给予该公司 “跑赢大盘” 的评级。瑞穗证券在 11 月 6 日的报告中将 Axsome Therapeutics 的目标价从 200.00 美元上调至 202.00 美元，并给予该股票 “跑赢大盘” 的评级。摩根士丹利在 11 月 4 日的报告中将 Axsome Therapeutics 的目标价从 194.00 美元上调至 196.00 美元，并给予该公司 “增持” 的评级。最后，B. Riley 在 10 月 1 日的研究报告中开始覆盖 Axsome Therapeutics 的股票。他们设定了 “买入” 评级和 179.00 美元的目标价。一位股票研究分析师对该股票给予了强烈买入评级，十六位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，共识目标价为 179.88 美元。</p>
</div><p><strong>View Our Latest Report on Axsome Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Axsome Therapeutics 的最新报告</strong></p>
</div><h2>About Axsome Therapeutics</h2>
<div class="lb-trans"><h2>关于 Axsome Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc.是一家生物制药公司，专注于在美国开发针对中枢神经系统（CNS）疾病的新疗法。该公司的商业产品组合包括 Auvelity（右美沙芬 - 布普洛尼），这是一种具有多重作用的 N-甲基-D-天冬氨酸受体拮抗剂，适用于治疗重度抑郁症；以及 Sunosi（索利美特），这是一种用于治疗嗜睡症或阻塞性睡眠呼吸暂停患者的白天过度嗜睡的药物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Axsome Therapeutics</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li>
<li>Best Aerospace Stocks Investing</li>
<li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>MarketBeat Week in Review – 12/1 - 12/5</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Axsome Therapeutics</li>
<li>投资者如何识别并成功交易缺口下跌股票</li>
<li>Ulta 的股票可能会迎来反弹——20% 的上涨空间？</li>
<li>最佳航空航天股票投资</li>
<li>比尔和梅琳达·盖茨基金会出售 MSFT 股票——投资者应该担心吗？</li>
<li>股息捕捉策略：您需要知道的事项</li>
<li>MarketBeat 周回顾 – 12/1 - 12/5</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AXSM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有 AXSM 的情况吗？</strong> 访问 HoldingsChannel.com 以获取 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AXSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Axsome Therapeutics 吗？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Axsome Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Axsome Therapeutics 并不在名单上。</p>
</div><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Axsome Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kennedy Capital Management LLC 增持了 Axsome Therapeutics, Inc. $AXSM 的股份